

# Protein-glycan interactions in the control of innate and adaptive immune responses

Yvette van Kooyk<sup>1</sup> & Gabriel A Rabinovich<sup>2</sup>

The importance of protein glycosylation in the migration of immune cells throughout the body has been extensively appreciated. However our awareness of the impact of glycosylation on the regulation of innate and adaptive immune responses is relatively new. An increasing number of studies reveal the relevance of glycosylation to pathogen recognition, to the modulation of the innate immune system, and to the control of immune cell homeostasis and inflammation. Similarly important is the effect of glycan-containing 'information' in the development of autoimmune diseases and cancer. In this review, we provide an overview of these new directions and their impact in the field of glycoimmunology.

Glycans cover the surfaces of all mammalian cells: they are added to protein and lipid backbones—a process called glycosylation—during the biosynthesis as these molecules are transported from the endoplasmic reticulum to the Golgi and the cell membrane. Glycosylation is mediated by a coordinated set of 'machinery' that involves glycosyltransferases, enzymes that catalyze the transfer of a sugar from a nucleotide sugar donor or a lipid sugar to a substrate, and glycosidases, enzymes that catalyze the hydrolysis of glycosidic bonds in glycan structures. Genes encoding this glycosylation machinery represent >1% of the total genome; to date more than 100 glycosyltransferases and glycosidase enzyme genes have been cloned that contribute to the selective addition and/or removal of particular monosaccharides to or from a 'growing' glycan structure<sup>1</sup>. The expression of these enzymes is highly regulated according to cell metabolism, activation, microenvironmental changes and aging. Therefore glycosylation itself can give different structural variations to a given protein, leading to identical proteins linked to different glycan structures (glycoforms). This diversity of glycans and enzymes gives the mammalian glycome an estimated variation of thousands of potential glycan structures, which adds to the diversity already created by the proteome. Within the mammalian glycosylation repertoire [AU: Edited to avoid calling glycosaminoglycans 'glycosylation machinery'; OK?], N-linked glycosylation, O-linked glycosylation and glycosaminoglycans have been identified (Fig. 1). The presence of potential N- and O-linked glycosylation sites in a protein backbone, together with the presence or absence of glycosyltransferases and glycosidases in the endoplasmic

reticulum, are key elements in determining the extent and nature of the glycosylation of a given protein.

Many eukaryotic and prokaryotic microbes express glycoconjugates on their surface or on secreted products. Whereas prokaryotic microbes generate other [AU: "other" as meant? (vs. "various")] types of glycan structures, many eukaryotic microbes synthesize N- and O-linked glycans, which resemble mammalian glycans in the core structure. Glycans from both prokaryotic and eukaryotic pathogens (for example, meningococci, *Trypanosoma* and *Helicobacter*), however, can include terminal glycan structures that are similar to those in mammalian glycans (so-called 'molecular mimicry'). In addition, other microbes, such as *Schistosoma mansoni* and *Mycobacterium tuberculosis*, express specific glycan epitopes including those identified in common pathogens<sup>2</sup>. [AU: Please clarify "common pathogens" — how do they relate to *S. mansoni* & *M. tuberculosis*? Also edit "microbes" (change to "pathogens"?) to reflect metazoan nature of *Schistosoma*.]

## Glycan recognition by proteins

Within the immune system, various classes of glycan-binding receptors (lectins) exist that recognize specific glycan structures presented on a protein backbone or lipid structure. These receptors are secreted or are found on the cell surface of immune cells. In this review we will focus on three receptor families that are involved in glycan recognition: galectins, C-type lectins and siglecs<sup>3–6</sup>. The glycan specificity of these receptors is well documented, as is their cell-specific expression and secretion (Supplementary Table 1 online [AU: Please email us a title for Supplementary Table 1]). Whereas galectins are secreted, most C-type lectins and all known siglecs are membrane-bound proteins. All these lectins contain one or more carbohydrate-recognition domains (CRDs) responsible for glycan binding.


Galectins are a family of soluble lectins defined by a common structural fold and a conserved CRD of about 130 amino acids that recognizes glycans containing the disaccharide *N*-acetylglucosamine (Gal- $\beta$ (1-4)-GlcNAc: Gal, galactose; Glc, glucose, NAc, *N*-acetyl-)<sup>3,7</sup>. [AU: All abbreviations OK as defined, and linkage notation OK as edited?] As many as 15 galectins have been identified in mammals<sup>8</sup>. Some galectins (galec-

<sup>1</sup>Department of Molecular Cell Biology and Immunology, VU University Medical Centre, v.d. Boechorststraat 7, 1081BT Amsterdam, The Netherlands.

<sup>2</sup>Laboratory of Immunopathology, Institute of Biology and Experimental Medicine, National Council of Scientific and Technological Research, C1428ADN, Ciudad de Buenos Aires, Argentina.

Correspondence should be addressed to Y.v.K. (y.vankooyk@vumc.nl) or G.A.R. (gabyrabi@ciudad.com.ar). [AU: (i) Please spell out VU and v.d. (ii) Listed both authors as corresponding authors; as desired? (iii) Is e-mail address case-sensitive? We style all lower case otherwise.]

Published online XX Month 2008; doi:10.1038/ncx



**Figure 1** N- and O-linked glycosylation. The enzymatic process of vertebrate glycosylation uses several monosaccharides (fucose, galactose, *N*-acetylgalactosamine, glucose, *N*-acetylglucosamine, glucuronic acid, mannose, sialic acid and xylose)<sup>1</sup>. This results in a large variety of possible glycans owing to the many different types of anomeric linkages that are possible between two monosaccharides and to the formation of branches within the glycan structures. These characteristics determine the physical, three-dimensional orientation [AU: orientation or shape? or both?] of the glycan, which is critical for recognition by carbohydrate-binding molecules. N-glycans are covalently linked to asparagine residues of proteins, specifically the Asn-X-Ser/Thr motif. In contrast, O-glycans are attached to a subset of glycosidically linked hydroxyl groups of the amino acids serine (with H moiety, shown in parentheses), threonine (with CH<sub>3</sub>) or hydroxylysine (not shown) [AU: Legend and caption OK as edited, to match structure shown?]. N-glycosylation biosynthesis starts with the high-mannose structure, followed by trimming and branching of glycans and the sequential addition of a variety of monosaccharides, depending on the glycosyltransferases present, thus creating a wide diversity of N-glycan structures. In contrast, O-glycosylation starts with the addition of a single monosaccharide, such as  $\alpha$ -GalNAc in the conventional mucin-type O-glycosylation, attached to serine or threonine. This single GalNAc residue can be extended to form different O-glycan core structures, which can be further elongated to generate more complex glycosylation. AchN, *N*-acetyl group. [AU: Added; OK? (linear 'shorthand' nonstandard in structural formulas)]

tins 1, 2, 5, 7, 10, 11, 13, 14 and 15), which are traditionally classified as 'prototypical' [AU: "prototypical" as meant?] galectins, have one CRD that can dimerize, whereas others (galectins 4, 6, 8, 9 and 12), so called 'tandem-repeat galectins', contain two homologous CRDs in tandem in a single polypeptide chain, separated by a linker of up to 70 amino acids. Galectin-3 is, as far as we know, unique in that it contains a CRD connected to a non-lectin N-terminal region (about 120 amino acids) that is responsible for oligomerization of the lectin and ligand cross-linking<sup>3,9,10</sup>. The presence of more than one oligosaccharide-recognizing CRD in a galectin-1 [AU: Galectin-1 only, or all prototypical galectins?] homodimer makes the homodimer well suited for mediating cell adhesion, eliciting signaling and forming cell-surface lattices<sup>8,9</sup>, whereas tandem-repeat galectins are intrinsically bivalent, although the two CRDs may recognize different saccharide ligands<sup>3</sup>. Some galectins, such as galectin-1 and galectin-3, are distributed in a wide variety of tissues, whereas others, such as galectin-4 and galectin-10, have more restricted localizations. In the immune system, galectins are mostly expressed by activated but not resting T and B cells, and they are significantly upregulated in activated macrophages and regulatory T cells<sup>8,9</sup>. Although these soluble lectins do not have the signal sequence required for the classical secretion pathway, they are secreted into the extracellular milieu through an atypical secretory mechanism<sup>3,8,9</sup>.

C-type lectin receptors (CLRs) are calcium-dependent carbohydrate-binding proteins and consist of a large family of receptors (60–80) that is further divided into subfamilies<sup>6,11,12</sup> (<http://www.imperial.ac.uk/research/animallectins/ctld/mammals/humandata.html>). Several of these C-type lectins (the natural killer (NK) cell receptor-like family) have no classical CRD domains and thus are not involved in protein-gly-

can interactions<sup>5,6,11</sup>. However most CLRs are glycan-binding receptors, as they carry one or more CRD regions. C-type lectins can be divided into two categories on the basis of an amino acid motif involved in glycan recognition and coordination of the Ca<sup>2+</sup> ion. The mannose-specific C-type lectins contain an EPN (Glu-Pro-Asn) amino acid motif and have a specificity for mannose [AU: Please clarify: mannose, or mannose-terminated? and, below, galactose or galactose-terminated?] and/or fucose-terminated glycans. In contrast, the galactose-specific C-type lectins contain the QPD (Gln-Pro-Asp) sequence in the CRD and recognize galactose or GalNAc-terminated glycan structures<sup>5,6,12</sup>. The type II subfamily of CLR, of which 17 members have been cloned in human, is mainly restricted to antigen presenting cells (APCs) such as macrophages and dendritic cells (DC); some have also been identified on NK cells or endothelial cells<sup>5,6,12</sup>. Maturation of DCs often results in loss of CLR expression<sup>12</sup>. CLRs such as DC-SIGN, L-SIGN, mannose receptor, macrophage galactose-specific lectin (MGL) and langerin are well characterized for their specificity for high-mannose, fucose-containing glycans (Lewis<sup>a,b,x,y</sup>), GalNAc or GlcNAc<sup>5,13–16</sup>. These glycan structures can be expressed by mammalian cells or by pathogens, reflecting their dual function in host-pathogen recognition and immune cell responses. In contrast, dectin-1, a Ca<sup>2+</sup>-independent CLR, is specific for  $\beta$ -glucan, a fungus-specific glycan<sup>17,18</sup>. [AU: Sentence OK as edited?] Typically, CLRs show regulated specificity for clustered glycans (polyvalency) that increases their affinity<sup>13,19</sup>. [AU: Please clarify "regulated"] Polyvalency is often achieved by the expression of glycans on protein backbones that contain multiple repeating subunits, such as mucin-like molecules, or pathogen-related structures [AU: Please clarify "pathogen-related structures" (how the phrase fits into the sentence syntax, and what


kind of structures are meant)] or by the expression of multiple copies of a given protein carrying the specific glycans. Such glycan-enhanced [AU: Clarify “glycan-enhanced” (vs just “enhanced”) — do you in fact mean avidity enhanced by glycans?] avidity of a given CLR coincides with the formation of multimers [AU: “formation of multimers” as meant? (vs structure consisting of multimers)] of these receptors in cell membranes<sup>6,15</sup>. Finally, C-type lectins have been described to function as patterns for pathogen recognition receptors and as [AU: “as” as meant? (vs “for”)] receptors for antigen uptake, signaling and cell adhesion<sup>20</sup>.

Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of type I membrane proteins with variable numbers of immunoglobulin domains. On the basis of sequence similarity and evolutionary conservation, they can be divided into two types: CD33-related siglecs (Siglecs 3, 5, 6, 7, 8, 9, 10, 11 and 14) and sialoadhesin (Siglec-1, CD169), MAG (Siglec-4) and Siglec-2 (CD22)<sup>4</sup>. [AU: Please clarify: (i) Are Siglec-1 and CD169 alternative names for the same thing, or is that a list of two different proteins, as in the immediately preceding parentheses? (ii) How do the four items in the overall list correspond to the two types?] These glycan-binding proteins are well known for their specificity for sialic acid-containing glycans (of which *N*-acetylneuraminic acid is the most common)<sup>4,21,22</sup>. Sialylated structures are often found on the nonreducing ends of oligosaccharides chains of *N*- or *O*-linked glycans or on glycosphingolipids. All siglecs recognize sialylated structures but can differentially discriminate among specific linkages ( $\alpha(2-3)$ ,  $\alpha(2-6)$  or  $\alpha(2-8)$ ) by which the sialic acid structures are linked to the underlying glycan structure and can selectively distinguish structural features of the glycans themselves<sup>4</sup>. For the CD33-related siglecs and CD22 (Siglec-2) the presence of immunoreceptor tyrosine-based inhibitory motifs (ITIM) motifs or ITIM-like motifs in the cytoplasmic tail can modulate cellular functions by recruitment of signaling molecules<sup>4</sup>. At present, 13 members of the siglec family, which are widely expressed on immune cells, including neutrophils, monocytes, B cells DC, NK cells, eosinophils and basophils, have been identified in humans. However, expression on human T cells is barely detectable. In addition, sialic acid structures can be found on pathogens, illustrating the bifunctional role of siglecs in both pathogen recognition and intercellular communication of immune cells<sup>4</sup>.

Uniquely (to our knowledge), siglecs can mediate *cis* and *trans* interactions with sialylated glycans<sup>4</sup>. In the case of *cis* interactions, the siglec is often masked by low-affinity ligands on neighboring membrane receptors. Because the local concentration of sialic acid on the surface of immune cells is very high, the siglec-binding sites may typically be masked by *cis* interactions with glycan ligands expressed on the same cell, indicating that *cis* interactions may play a dominant role in modulating immune responses. However, *cis* interactions do not necessarily prevent *trans* interactions<sup>23</sup>.

### Control of innate immune responses

The capacity to recognize glycans from divergent organisms such as bacteria, yeast, viruses and helminth parasites underlies a mechanism for pathogen recognition. This is illustrated by Toll-like receptor (TLR) activation of innate immune system through binding to bacterial glycans<sup>24</sup>. Likewise, many CLRs are expressed on innate immune cells, particularly macrophages and DCs; these APCs are the first line of defense responsible for clearing pathogens, and they subsequently initiate adaptive immune responses. The DC-expressed C-type lectins mannose receptor (CD206), DC-SIGN (CD209), MGL (CD301) and dectin-1, as well as langerin (CD207) on Langerhans cells, are involved in glycan-mediated pathogen recognition and internalization of antigen for loading on major histocompatibility complex (MHC) class I and II molecules (Fig. 2)<sup>12,20,25</sup>. Thus, CLRs can function as pathogen recognition receptors



**Figure 2** Glycan-binding proteins involved in pathogen interaction leading to antigen presentation and signaling in APC. Many C-type lectins and several siglecs (Siglecs 1, 5, 7 and H) are pathogen recognition receptors that interact with specific glycan structures on these pathogens, such as Lewis<sup>x,y</sup>, GlcNAc, high-mannose structures, sialic acids and GalNAc. [AU: “Lewis<sup>x,y</sup>” and “high-mannose structures” OK as edited?] and mediate internalization and enhanced antigen processing and presentation by MHC class I and II. Soluble galectins can interact with pathogens, forming lattices and initiating innate immune responses. [AU: Sentence correct as edited?] Pathogen recognition by C-type lectins and siglecs expressed on APCs can lead to different [AU: Please clarify: “various”? or different from the aforementioned (lattice formation etc)?] intracellular signaling processes and modulate TLR signaling or elicit signaling independently of TLR activation. Galectins can interact with certain glycoproteins expressed by APCs, thereby modulating APC maturation and cytokine production. Gal, galectin. [AU: (i) As meant for Gal? (ii) Please describe role of MyD88 or otherwise define this molecule]

that favor enhanced antigen presentation and antigen-specific T cell induction<sup>26</sup>. However, the glycans that CLRs recognize are often not actually pathogen specific; for example, many similar glycans can be found in mammalian cells. Yet some pathogen-specific glycans do occur, such as pseudo-Lewis<sup>y</sup>, a pathogen-specific glycan structure recognized by DC-SIGN<sup>27</sup>.

Many reports have provided evidence that CLRs are signaling receptors that, together with activated TLRs, ‘relay information’ about specific pathogens into DC differentiation and immune-response programs by affecting the expression of cytokine genes<sup>5,16,18,28–30</sup>. A well described example is the signaling function of the CLR dectin-1 upon recognition of fungal  $\beta$ -glucan structures, which triggers signal by the Syk tyrosine kinase [AU: OK as defined?] and activates the p38, Erk and JNK kinase cascades and the transcription factor NF- $\kappa$ B (ref. 18). For this signaling, the adaptor CARD9, which forms complexes with signaling molecules Bcl-10 and MALT1, is required, thus defining a pathway by which a CLR, independently of TLRs, regulates innate gene expression<sup>31</sup>. Recently, the CLR DC-SIGN has also been shown to signal upon recognition of pathogen glycan components, through in this case it does so through activation of the kinase Raf-1, which translates the signal into phosphorylation and subsequent acetylation of the activating NF- $\kappa$ B subunit p65 and thus increases transcription of specific cytokine genes<sup>28</sup>. Distinct from dectin signaling, DC-SIGN-mediated signaling is dependent on


TLR-induced activation of NF- $\kappa$ B and can in fact modulate TLR-dependent signaling<sup>28</sup>.

Pathogens that simultaneously target CLR and TLRs have been shown to modulate DC responses depending on their pathogen-specific glycan signatures, which, as described earlier, critically affect CLR binding. High-mannose structures on the cell-wall component ManLAM of *M. tuberculosis* ‘target’ the mannose receptor and DC-SIGN to induce signaling that leads to the production of anti-inflammatory cytokines such as interleukin (IL)-10 (refs. 20,26), whereas phase variants of *Helicobacter pylori* expressing the Lewis<sup>x</sup> (CD15) and Lewis<sup>y</sup> (CD174) glycan antigens on the lipopolysaccharide O-antigen ‘target’ DC-SIGN on DCs to induce signaling that leads T cells to differentiate into T helper type 2 (T<sub>H</sub>2) cells<sup>32</sup>. Similarly, *S. mansoni* soluble egg antigens expressing fucosylated LacdiNAc [AU: Please spell out using lactosediamine. Note: LDN deleted; OK?] sequences and Lewis<sup>x</sup> [AU: Changed from Lewis-X for consistency; OK?] antigens or pseudo-Lewis<sup>y</sup> in the cercaria of the parasite ‘target’ DC-SIGN to ‘instruct’ DCs to stimulate the production of T<sub>H</sub>2 responses<sup>33</sup>. In contrast, viral capture through high-mannose HIV-1 gp120 by langerin on Langerhans cells leads to viral elimination, whereas DC-SIGN on dermal dendritic cells enhances HIV-1 infectivity<sup>34–37</sup>. The C-type lectin MGL, with specificity for terminal  $\alpha$ - or  $\beta$ -GalNAc<sup>16</sup>, can recognize pathogens such as filovirus<sup>38</sup> and helminth parasites such as *S. mansoni* that express terminal GalNAc moieties<sup>16</sup>.

Over 20 pathogenic microorganisms are known to have evolved the capacity to synthesize sialic acids from their hosts [AU: Please clarify “synthesize from”: synthesize the same sialic acids found in their hosts, or extract sialic acids from their hosts?] and incorporate these moieties into their own glycoconjugates. Sialylation of glycoconjugates in these pathogens seems to be crucial for their survival in the mammalian hosts, possibly serving as molecular mimics of the host cell surfaces to avoid immune attack—by silencing the alternative complement pathway activation, by resisting phagocytosis or by engaging inhibitory siglecs. Siglec-1, Siglec-5 and Siglec-7 have been shown to be potentially [AU: Is it shown or is it just potential?] involved in host-pathogen interactions of pathogens such as porcine reproductive and respiratory syndrome virus<sup>4</sup>, *Neisseria meningitidis*, *Campylobacter jejuni*, *Trypanosoma cruzi* and Streptococcus group B<sup>4,39</sup>; and pathogen binding to Siglec-1 leads to enhanced pathogen endocytosis and uptake by macrophages (Fig. 2). In addition, Siglec-H, expressed on mouse plasmacytoid DCs, has a role in viral capture and antiviral immunity, as it has been shown to function as an endocytic receptor that internalizes antigen for presentation to T cells<sup>40</sup>. Remarkably [AU: Please rephrase: specify what is remarkable about it], Siglec-F and Siglec-G show inhibitory effects on the activation of T and B cells, respectively<sup>41</sup>.

Galectins may also influence immunity by interacting with  $\beta$ -galactoside-enriched glycoconjugates present in several pathogens<sup>8</sup>. Although the nature of these interactions is still not well characterized, galectin oligomerization and/or lattice formation are likely to play a role<sup>42,43</sup>. For example, galectin-3 binds the lipophosphoglycan of *Leishmania major*, and this binding leads to the proteolytic removal of the galectin-3 N-terminal domain, preventing oligomerization and lattice formation; galectin-9 also recognizes *L. major* by binding to lipophosphoglycan, and this binding promotes glycan-dependent *L. major*–macrophage interactions<sup>42</sup>. Furthermore, galectin-3 acts a pathogen recognition receptor for LacdiNAc-containing glycans present in helminth parasites<sup>43</sup>. In fact, galectins have been proposed to act as ‘alarmins’ by sensing danger signals and converting them into activation signals for innate immune cells<sup>44</sup>. Galectin-3-mediated ligand clustering triggers neutrophils to phagocytose, produce reactive oxygen species, release proteases and secrete the chemokine IL-8 (ref. 44). In addition, galectin-3 expression can also alter histamine release and IL-4 synthesis by

Lymphocyte homeostasis



**Figure 3** Lectin-glycan interactions in the control of immune cell homeostasis. Lectins are involved in the modification of various cellular interactions owing to the differential glycosylated state of particular counter-receptors. Many studies have shown inhibitory control mechanisms on effector T cells, such as induction of apoptosis by galectin binding to glycosylated CD45, CD43 or TIM-3 or action through C-type lectin-glycan interactions including MGL-CD45 interactions that take place between tolerogenic APCs and effector T cells. Certain glycoreceptors (CD43, CD45, MUC-1) can be recognized by C-type lectins, galectins and siglecs, depending on their glycosylation status. Synapse formation between APCs and T cells can be regulated by galectin-3 and by DC-SIGN and ICAM-3. APC and [AU: “and” as meant?] B cell function can be altered by Siglec-1, Siglec-2 and galectin-1, thus affecting BCR signaling. In particular, galectin-1 can induce IL-10 production, promote the expansion of regulatory T cells and induce apoptosis of T<sub>H</sub>1 and T<sub>H</sub>17 effectors through specific glycan recognition, thus favoring the development of T<sub>H</sub>2 responses. Gal, galectin.

mast cells<sup>45</sup>. In contrast, galectin-1 has been shown to contribute to resolution of the acute inflammatory response, as it inhibits mast cell degranulation, blocks neutrophil recruitment to sites of inflammation and promotes phosphatidylserine exposure, thus preparing neutrophils for rapid apoptosis<sup>46–48</sup>. Moreover, at the interface of innate and adaptive immunity, galectin-9 binding to specific glycoproteins ‘favors’ the maturation of human monocyte-derived DCs<sup>49</sup>, and expression of galectin-1 upregulates a substantial subset of genes related to DC migration<sup>50</sup>. In addition, expression of galectin-1 and/or galectin-3 can mediate alternative activation of macrophages, which is clearly illustrated by the inability of IL-4 to induce alternative macrophage activation in *Lgals3*<sup>-/-</sup> (galectin-3-deficient) mice<sup>51</sup> and the ability of galectin-1 signaling to ‘skew’ L-arginine metabolism toward increased arginase activity in peritoneal macrophages<sup>52</sup>. Partridge and colleagues proposed a glycosylation-dependent mechanism by which galectin-3 cross-linking to complex N-glycans on cytokine receptors may delay their cell surface removal by endocytosis and promote sustained cytokine signaling on leukocytes<sup>53</sup>.

Thus, galectins work as versatile molecules capable of modulating the physiology of different innate immune cells by acting either as cyto-

kines, adhesion molecules or modulators of the immunological synapse. In contrast, most C-type lectins and Siglec-1 are antigen-uptake receptors that facilitate MHC-restricted antigen presentation to T cells. These lectins [AU: Please clarify: both galectins and C-type lectins, or only C-type lectins?] are considered powerful signaling receptors that positively or negatively instruct DC differentiation and subsequent T cell responses.

### Homeostasis of adaptive immune responses

Identification of endogenous factors that control immune tolerance and homeostasis is a key challenge in the field of immunology. Most immune cells are heavily sialylated, which often shields the glycans from recognition by CLR. However, when cells modify their sialylation pattern, glycans are exposed to allow new CLR-ligand interactions. In this regard, DC-T cell synapse formation can be regulated by DC-SIGN and the adhesion molecule ICAM-3, which is present on a minor population of naive T cells<sup>35</sup>. In addition, DC-SIGN can interact with endothelial Lewis<sup>x</sup>-expressing ICAM-2, which is controlled by the fucosyltransferase FUT1 (Fig. 3 and Supplementary Fig. 1 online). Small interfering RNA 'silencing' of FUT1 results in reduced migration and reduced [AU: "reduced" as meant?] rolling of immature DC on endothelial cells<sup>54</sup>. Neutrophils that [AU: "that" as meant? (vs "which"—i.e., all neutrophils)] express high levels of Lewis<sup>x</sup> (CD15) glycans show enhanced binding to immature DC through DC-SIGN<sup>55</sup>.

Cellular interactions between neutrophils and immature DCs have an important function in the transition from innate to adaptive immune responses, whereby activated neutrophils 'instruct' DCs to mature and then to 'trigger' T cell signaling. In particular Lewis<sup>x</sup> on both MAC-1 and CEACAM-1 [AU: Please spell these out or provide a brief functional definition (e.g., "the cell adhesion molecules")] on neutrophils functions as a 'ligand' for DC-SIGN<sup>55</sup>. This highlights the fact that the cell-specific glycosylation machinery can differentially affect recognition by carbohydrate-binding proteins (Fig. 3 and Supplementary Fig. 1). In fact, neutrophils contain high expression of FUT-9, which is involved in the biosynthesis of specific Lewis<sup>x</sup> glycans. Another cell-specific ligand for DC-SIGN recently identified is the B7 costimulatory molecule-related BTN2A1 (Supplementary Table 1). Also, the C-type lectin MGL, primarily expressed on tolerogenic DCs, has been shown to interact with a subset of CD4<sup>+</sup> and/or CD8<sup>+</sup> effector T cells<sup>16,56</sup>. The MGL ligand on these T cells was identified as CD45, which exposes terminal GalNAc (Tn) structures for recognition by MGL. More importantly, binding of MGL to CD45 triggers the phosphatase activity of CD45 that results in enhanced apoptosis of T cells and reduced secretion of proinflammatory cytokines<sup>56</sup>.

As soluble lectins, galectins can also modulate immune effector functions by controlling cell activation, cytokine synthesis and viability through cross-linkage of glycoreceptors on the surfaces of T and B cells<sup>8</sup>. Galectins 1, 2, 3 and 9 can bind distinct cell-surface glycoprotein receptors and signal different intracellular pathways, negatively regulate T cell survival and homeostasis<sup>57–60</sup>. Although many glycoproteins contain substantial amounts of lactosamine-containing glycoconjugates, different members of the galectin family bind to a restricted set of T cell surface glycoproteins (that is, CD43, CD45, CD7, CD29, CD71, TIM-3)<sup>57–60</sup>. However, what ultimately controls galectin binding to the surface of T cells is the activity of different glycosyltransferases creating or masking specific ligands for these endogenous lectins<sup>61,62</sup>. Likewise, formation of immune synapses between pre-B and stromal cells, which triggers signal transduction from the pre-B cell receptor (pre-BCR), is galectin-1-dependent<sup>63</sup>. [AU: Sentence as meant?]


Sialic acid-dependent siglec-1 interactions can regulate binding to mucin-like molecules that are covered with high densities of sialylated

O-linked glycans. As such, MUC-1 and CD43 have been identified as counter-structures [AU: (i) Please explain counter-structures. Ligands? (ii) Define abbreviation MUC-1 (spell out or provide a brief function definition)] for Siglec-1; these receptors can mediate cellular contact between T cells and Siglec-1-expressing macrophages<sup>4</sup>. CD22 (Siglec-2) is also a well documented regulator of B cell signaling, homeostasis and survival<sup>64–66</sup>, and helps set the threshold for antigen-induced B cell activation<sup>4</sup>. B cell receptor ligation leads to increased phosphorylation of the cytoplasmic tail of CD22, which recruits phosphatases (for example, SHP1) to downmodulate BCR signaling. And CD22-deficient mice indeed show a hyperimmune response (ref. 67). [AU: CD22 sentences OK as edited?] Cellular activation may reduce the masking and *cis*-ligand occupation by desialylation to expose siglecs for *trans* interactions, allowing colocalization of BCR-CD22 complexes in rafts<sup>64,68,69</sup> (Fig. 3). In addition, many members that belong to the CD33-related siglecs (Siglecs 3, 5, 6, 7, 8, 9, 10, 11 and 14) are expressed by mature cells of the innate immune system, including neutrophils, eosinophils, macrophages, DCs and NK cells<sup>4</sup>. They have been described to inhibit cellular proliferation, induce apoptosis and block cellular activation; these effects are probably attributable to ITIM motifs present in the siglec cytoplasmic tails<sup>4</sup>.

### Protein-glycan interactions in inflammation and autoimmunity

In several inflammatory autoimmune diseases, such as systemic lupus erythematosus, effector T cell populations with altered T cell glycosylation, especially those exposing terminal GalNAc structures, are highly upregulated<sup>70</sup>. Both MGL and galectins interact with these structures, and have been proven to downmodulate T cell antigen receptor (TCR)-mediated signaling and affect the phosphatase function of CD45 (ref. 56). Indeed, several indications hint at an involvement of galectins in suppression of chronic inflammation. Treatment with galectin-1 suppresses chronic inflammation in several models of autoimmunity by skewing the balance of the immune response toward a T<sub>H</sub>2 cytokine profile<sup>8,71–73</sup>. In particular, T<sub>H</sub>1 and T<sub>H</sub>-17 effector cells express the repertoire of cell surface glycans that are essential for galectin-1 binding and subsequent cell death. By contrast, T<sub>H</sub>2 cells are resistant to galectin-1 binding through differential  $\alpha(2-6)$  [AU: Notation OK as edited?] sialylation of cell surface glycoproteins<sup>73</sup>. Accordingly, galectin-1-deficient (*Lgals1*<sup>-/-</sup>) mice develop greater antigen-specific T<sub>H</sub>1 and T<sub>H</sub>-17 responses than do wild-type mice<sup>73</sup>. Similarly to galectin-1, galectin-2 induces apoptosis of activated T cells and ameliorates inflammatory bowel disease<sup>58</sup>; and, in addition, galectin-9 acts as a specific binding partner of TIM-3, a T<sub>H</sub>1-specific receptor, and selectively dampens T<sub>H</sub>1 responses *in vivo* in a model of autoimmune neuro-inflammation<sup>60</sup>. However, recent evidence indicates that engagement of TIM-3 by galectin-9 can also favor tissue inflammation by synergizing with TLR on DCs<sup>74</sup>. Remarkably [AU: Please rephrase], galectin-4 contributes to exacerbated inflammation by perpetuating CD4<sup>+</sup> T cell activation and increasing IL-6 secretion<sup>75</sup>. Galectin-1 also contributes to immune tolerance by enhancing IL-10 production<sup>76</sup> and fostering the expansion of IL-10-producing regulatory T cells in mouse models of autoimmunity, fetal loss and cancer<sup>71,77,78</sup>. Thus, galectin-1 halts inflammatory and autoimmune responses by modulating the T<sub>H</sub>1–T<sub>H</sub>2 cytokine balance, by inducing T cell apoptosis and by facilitating the expansion of IL-10-secreting regulatory T cells. Notably, galectin-1 and galectin-10 are overexpressed in CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells and have been reported to be essential for the immunosuppressive activity of these cells<sup>79,80</sup>.

Notably, multivalent galectin-3–N-glycan lattices can limit TCR clustering at sites of immunological synapse and increase agonist threshold for TCR signaling, and thus they may contribute to T cell homeostasis<sup>81</sup>. Galectin-1 can also interfere with the assembly of the immunological



**Figure 4** Glycan modifications during tumor development results in selective recognition by lectins and modulation of immune responses. Malignant transformation often correlates with altered glycosylation of glycoproteins on the surface of tumor cells. These glycosylation changes, which have been widely used as prognostic markers of disease progression, can be detected by several galectins and C-type lectins (MGL and DC-SIGN). The binding of these lectins to altered glycoproteins may affect APC function, leading to anti-inflammatory responses. Alternatively, galectins synthesized by the tumor may target the survival and proliferation of effector T cells, skew the balance toward a  $T_H2$  cytokine profile, and/or induce the expansion of regulatory T cells to favor immune escape by the tumor. CEA, carcinoembryonic antigen; Le, Lewis; SLe, sialylated Lewis; TF, Thomsen-Friedenreich disaccharide.

synapse by limiting the recruitment of kinases and the exclusion of phosphatases [AU: Please clarify: by limiting the exclusion of phosphatases, or by excluding phosphatases?] such as CD45 near to the TCR-CD3 complex, thus antagonizing T cell functions such as T cell proliferation and IL-2 secretion that require sustained signal transduction<sup>82</sup>. Galectin-carbohydrate lattices can therefore control T cell-mediated inflammation through multiple mechanisms, affecting the survival, signaling and functionality of effector and regulatory cells.

C-type lectins also play a role in the modulation of inflammatory and autoimmune diseases. *In vivo*, targeting a central nervous system peptide to the CLR DEC205 on immature mouse [AU: As meant for murine throughout? (vs mouse and rat, Murinae)] DCs induces tolerance in experimental autoimmune encephalomyelitis (EAE)<sup>25</sup>. Similarly, mannosylated myelin proteolipid protein peptides can inhibit the onset of EAE in mice, probably by targeting the mannose receptor on immature DCs, whereas unglycosylated peptides induce severe EAE<sup>83,84</sup>. These findings indicate that the natural function of CLRs as antigen uptake receptors is associated with the maintenance of tolerance for homeostatic control<sup>26</sup>. In contrast, certain siglecs, such as Siglec-1 (sialoadhesin), are upregulated by inflammatory macrophages; for example, in proliferative glomerulonephritis, the expression of Siglec-1 correlates with proteinuria<sup>85</sup>. At the same time, Siglec-1 may modulate T cell function and activation during immune responses, as sialoadhesin-deficient mice show reduced inflammation owing to reduced influx of macrophages and T cells to inflammatory sites<sup>4</sup>.

### Protein-glycan interactions in tumor immunity

In recent years many laboratories have made considerable efforts to identify a 'poor prognosis signature' of tumor- and metastasis-associated genes and to predict the clinical outcome of neoplastic disease. Changes in glycosylation have been shown to strongly associate with the development of cancer and metastasis<sup>86</sup>. This differential glycosylation of cancerous and healthy tissues is often restricted to altered glycan expression of tumor cells or their secreted glycoproteins. In many cases, the structural changes have been further correlated with changes in the activity of one or more glycosyltransferases during the process of transformation from normal to tumor cells<sup>86</sup> (Supplementary Fig. 1) Changes in glycosylation could result in loss of cell adhesion, an event associated with increased cell invasiveness of primary tumors to distant sites. Notably, the metastatic potential of some tumor cells has been extensively correlated with increased sialylation of cell surface glycoproteins, which is consistent with the known ability of sialic acid-binding lectins such as selectins to

mediate cell adhesion and extravasation during the metastatic process (Fig. 4 and Supplementary Fig. 1)<sup>87–89</sup>. Also, loss of disialyl Lewis<sup>x</sup> [AU: Changed A to <sup>a</sup> 2x; OK?] structures (for example, ligands for Siglec-7), an occurrence associated with increased sialyl Lewis<sup>x</sup> (that is, ligands for E-selectin) in human colon cancers, induces loss or gain of function of lectin receptors<sup>90,91</sup>. In addition, several carbohydrate structures, such as Tn (GalNAc- $\alpha$ -Ser/Thr, CD175), sialyl Tn (*N*-acetylneuraminic acid- $\alpha$ 6-GalNAc- $\alpha$ -Ser/Thr, CD175s), Thomsen-Friedenreich disaccharide (Gal- $\beta$ (1-3)-GalNAc, CD176) [AU: Notation OK as edited? Also, should STn have both carbon numbers specified for the sugar-sugar linkage? Should Tn and STn have the sugar carbon number specified for the sugar-aa linkage?] and (sialylated) Lewis antigens (CD15s) are highly upregulated in malignant cells and have been widely used as diagnostic and prognostic markers<sup>87</sup>. Monoclonal antibodies to these glycan epitopes have been used for the detection of tumor growth and metastasis, to monitor disease status and the effectiveness of different therapies.

The recent finding that several of these tumor-related glycoforms of carcinoembryonic antigen<sup>88</sup> and MUC-1 (ref. 89) form counter-structures [AU: (i) CEA spelled out correctly? (ii) spell out MUC-1. (iii) Please explain or reword counter-structures] for CLRs expressed on DCs, such as DC-SIGN and MGL, opens up a new area of exploring whether these specific glycoforms affect [AU: Changed from "effect"; as meant? (vs "implement")] CLR signaling and DC differentiation, thereby modulating innate and adaptive antitumor responses. Expression of Tn epitopes on MUC-1 is associated with poor prognosis in several types of cancer<sup>86</sup>; of note, Tn glycans on MUC-1 bind MGL and instruct DC to drive  $T_H2$ -mediated responses, which, unlike those of  $T_H1$  effector cells, do not contribute to tumor eradication. These findings illustrate the relevance of altered glycosylation in the tumor microenvironment in the impaired function of DCs. Studies *in vitro* and *in vivo* in both mice and human have demonstrated that high-affinity binding structures, such as antibodies and glycans, may be used to 'direct' vaccine vehicles to CLRs on DC and thus stimulate antigen-specific T cell responses. For example, the C-type lectins langerin and DC-SIGN are expressed on LC and DC and have been successfully targeted for the subsequent generation of tumor-specific immunity<sup>92,93</sup>. Targeting CLRs thus may not only provide the DC-specific target but also may simultaneously facilitate antigen internalization for MHC- or CD1-mediated antigen presentation.

In addition to altered glycosylation, gene and protein expression profiles of tumors have repeatedly led to the identification of galectins as proteins that are expressed in a plethora of tumors and metastatic lesions<sup>9</sup>. Galectins can certainly influence tumor progression through

many mechanisms, including modulation of neoplastic transformation, tumor cell survival, angiogenesis and tumor metastasis<sup>9</sup>. Secretion of galectin-1 has been shown to contribute to the immunosuppressive activity of melanoma, Hodgkin's lymphoma and prostate cancer cells, suggesting the potential involvement of this protein in immune escape by tumors<sup>78,94,95</sup>. Hence, it is assumed that the galectin repertoire in the tumor microenvironment and the glycosylation pattern of inflammatory cells might be important in cancer progression and immuno-editing.

### Differential glycosylation control innate and adaptive responses

As highlighted above, glycans have enormous structural and functional diversity and are critical in a variety of biological processes, including those that are fundamental for the development and homeostasis of the immune response<sup>1,96</sup>. Most immune processes, including activation, differentiation and homing, are accompanied by a programmed remodeling of cell surface glycans, which themselves are the products of a repertoire of glycosyltransferases and glycosidases, acting sequentially and dictating the glycosylation 'signature' of each effector cell type<sup>96–99</sup>. The function of decoding the biological information encrypted by this glycosylation 'signature' is assigned in part to endogenous glycan-binding proteins or lectins (that is, C-type lectins, galectins and siglecs), whose expression and function are regulated at sites of inflammation<sup>96</sup>. A recent approach to decipher the 'glycomics' of the immune system revealed extensive changes, which critically affect the binding and signaling of glycan-binding proteins, in the expression of N- and O-glycans during T-cell activation<sup>97,98</sup>, T helper differentiation<sup>73,98</sup> and DC maturation<sup>99</sup>. In addition, changes in glycosylation are often hallmark of the transition from normal to inflamed or neoplastic tissue, providing new types of opportunities for therapeutic interventions<sup>87</sup>.

In recent years many gene knockout experiments have facilitated our understanding of the impact of O- and N-glycosylation pathways in immune cell function. Demetriou and colleagues found that targeted deletion of the locus encoding *N*-acetylglucosaminyltransferase-5, resulting in lack of  $\beta$ (1-6) branching of tri- and tetra-antennary complex N-glycans, ligands for galectin-3, enhanced T cell receptor (TCR)-mediated signaling and induced 'hyper- $T_H1$ ' responses and greater susceptibility to autoimmune disease<sup>81,98</sup>, which was the result of a restricted TCR aggregation by binding to galectins in the immunological synapse. The authors recently extended these findings showing that metabolite supply of the hexosamine pathway restores the high-affinity ligands for galectins, which suppresses TCR signaling and proliferation, inhibits  $T_H1$  skewing and prevents the development of autoimmune inflammation<sup>100,101</sup>. Furthermore, it has been reported that the lack of polyactosamine renders T cells, B cells and macrophages more sensitive to agonist-induced activation<sup>102</sup>. Thus, lattice formation after the binding of complex N-glycan to galectins effectively traps glycoprotein receptors at the cell surface and restricts cells' responsiveness to receptor agonists.

In addition to their contribution to T cell homeostasis and receptor turnover, a recent study highlighted a new, unpredicted role of N-glycans at the interface of innate immunity and autoimmune inflammation: this study described the development of a systemic lupus erythematosus-like syndrome in mice deficient in the enzyme  $\alpha$ -mannosidase II ( $\alpha$ M-II) that seems to be driven exclusively through a mechanism involving innate immunity<sup>103</sup>. The authors provided evidence that aberrantly expressed mannose-containing glycans in  $\alpha$ M-II null mice can elicit an innate immune response mediated by the C-type lectin MBL or mannose receptor<sup>103</sup>. These findings underscore a critical role for the mannose recognition system, classically exploited by pathogens to trigger innate immunity, in the initiation of organ-specific autoimmunity.

As with the N-glycan studies, recent efforts involving genetic manipulation of the O-glycosylation pathway have revealed essential roles of

O-glycans in immune system homeostasis<sup>96</sup>.  $\alpha$ (2-3)-Sialyltransferase I catalyzes sialic acid incorporation to [AU: Please clarify: addition to core, or incorporation into core?] core 1 O-glycans during protein O-glycosylation<sup>104</sup>. Deletion of the *St3gal1* locus, encoding this enzyme, yields constitutive exposure of unsialylated core 1 O-glycans, which were found to be associated with increases in CD8<sup>+</sup> T cells and contraction of the CD8<sup>+</sup> T cell compartment upon microbial challenge<sup>104</sup>. [AU: Please check (clarify as necessary): associated with both increases and contraction?] Hence, differential sialylation of cell surface glycoproteins may serve as an 'on-off' switch that controls the decisions between immune cell responsiveness or tolerance<sup>96,105</sup>. Notably, it has been reported that the differential  $\alpha$ (2-6) sialylation of the Fc region can control the pro- or anti-inflammatory effects of immunoglobulin G by modulating its binding to Fc $\gamma$  receptors<sup>105</sup>. In addition, aberrant glycosylation of immunoglobulins has been linked to the pathogenesis of diseases such as rheumatoid arthritis and immunoglobulin A nephropathy<sup>106,107</sup>. In particular, levels of agalactosyl and asialo glycoforms of immunoglobulin G have been shown to correlate with disease activity in rheumatoid arthritis in humans and in experimental autoimmune models<sup>106</sup>. Thus, differential sialylation can have a decisive role in the regulation of diverse immunological processes associated with immune cell tolerance and inflammation.

O-glycans are also the chief components of the intestinal mucus layer that covers the gastrointestinal epithelium and protects mucosal immune cells from potentially harmful pathogens. [AU: Should this be protects the immune cells, or protects the mucosa as a whole?] It has been recently found that deficiency of the core 3 transferase C3GnT results in elimination of core 3-derived O-glycans and presentation of naked Tn antigen in mouse colonic epithelium<sup>108</sup>. C3GnT-deficient mice have an increased susceptibility to inflammatory bowel disease and colorectal adenocarcinoma<sup>108</sup>, suggesting that core 3-derived O-glycans are key components of intestinal mucin and that disruption of these structures is associated with the initiation and perpetuation of intestinal inflammation. Notably, altered O-glycans are seen in more than 90% of colorectal cancers, which are strongly associated with ulcerative colitis. Thus, altered expression of glycosyltransferases would seem to modulate the glycosylation pattern of epithelial or immune cells and contribute to human pathology.

In this regard, a somatic mutation in *Cosmc*, a gene that encodes a molecular 'chaperone' that is required for proper folding and activity of the T-synthase [AU: Please explain what T-synthase is], was recently reported<sup>107</sup>. This mutation creates a truncated O-glycan composed of only *N*-acetylgalactosamine (Tn antigen); this seems to be the cause of a rare autoimmune disease called 'Tn syndrome', in which subpopulations of blood cells in all lineages carry an incompletely glycosylated membrane glycoprotein, as well as of other Tn-related syndromes such as immunoglobulin A nephropathy<sup>107</sup>. Thus, modifications on terminal N- and O-glycans provide distinct and essential contributions to innate and adaptive immune responses, with profound implications for the initiation and perpetuation of immune-mediated disorders.

### Conclusions and future directions

Advances in deciphering the information encoded by the 'glycome'—the entire repertoire of complex sugar structures expressed in cells and tissues—has created much interest in its potential biotechnological and pharmaceutical applications, but progress has been hampered by the inherent difficulties in studying the structure–function relationship of these complex molecules. However, innovative developments, including glycoarray technology and frontal affinity chromatography<sup>7,14,109</sup>, are rapidly changing the scene and creating opportunities for real progress over the next few years.

Recent efforts toward decoding the information contained in protein-saccharide interactions (**Supplementary Table 1**) have illuminated essential roles of glycan-binding proteins or lectins (that is, galectins, C-type lectins and siglecs) in host-pathogen interactions, initiation of innate immunity and modulation of immune tolerance and homeostasis. However, we are just beginning to understand the powerful contribution of protein-glycan interactions to the control of immune tolerance versus immunity, thus predicting a role for endogenous lectins and their specific saccharide ligands as potential targets for effective treatment of chronic inflammation, autoimmunity and cancer. Before these therapeutic strategies can be fully realized, however, there is still much to be learned concerning the contribution of glycan specificity and the nature of protein-glycan lattices in the amplification, silencing or tuning of innate and adaptive immune processes.

Note: Supplementary information is available on the Nature Immunology website.

#### ACKNOWLEDGMENTS

We apologize to the many authors whose papers could not be cited owing to space limitations. We thank all members of the Y.v.K. and G.A.R. laboratories for help and discussion, especially J.J. Garcia-Vallejo, S. van Vliet, M.A. Toscano, J.M. Ibarregui, G. Bianco; and H.F. Rosenberg, I. van Die and T.B.H. Geijtenbeek for critical reading of the manuscript. Supported by [AU: Note standard wording for acknowledgment of support. If work on this review has not been supported by these organization(s), omit them from the Acknowledgments] grants from Dutch Scientific Organization (NWO/ZONMW), Multiple Sclerosis [AU: Spelled out correctly?] Research Foundation the Netherlands, Association of International Cancer Research, VICI research institute VU Medical Centre [AU: Please spell out (or translate) VU and VICI], and Bridging Grant Consortium for Functional Glycomics (Y.v.K.) and by The Cancer Research Institute "Elaine R. Shepard" Award, Fundación Sales, Agencia Nacional de Promoción Científica y Tecnológica, University of Buenos Aires and Consejo Nacional de Investigaciones Científicas y Tecnológicas (G.A.R.).

Published online at <http://www.nature.com/natureimmunology>  
Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

- Ohtsubo, K. & Marth, J.D. Glycosylation in cellular mechanisms of health and disease. *Cell* **126**, 855–867 (2006).
- van Die, I. & Cummings, R.D. Glycans modulate immune responses in helminth infections and allergy. *Chem. Immunol. Allergy* **90**, 91–112 (2006).
- Leffler, H., Carlsson, S., Hedlund, M., Qian, Y. & Poirier, F. Introduction to galectins. *Glycoconj. J.* **19**, 433–440 (2004).
- Crocker, P.R., Paulson, J.C. & Varki, A. Siglecs and their roles in the immune system. *Nat. Rev. Immunol.* **7**, 255–266 (2007).
- Robinson, M.J., Sancho, D., Slack, E.C., LeibundGut-Landmann, S. & Reis e Sousa, C. Myeloid C-type lectins in innate immunity. *Nat. Immunol.* **7**, 1258–1265 (2006).
- Weis, W.I., Taylor, M.E. & Drickamer, K. The C-type lectin superfamily in the immune system. *Immunol. Rev.* **163**, 19–34 (1998).
- Hirabayashi, J. *et al.* Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. *Biochim. Biophys. Acta* **1572**, 232–254 (2002).
- Rabinovich, G.A., Toscano, M.A., Jackson, S.S. & Vasta, G.R. Functions of cell surface galectin-glycoprotein lattices. *Curr. Opin. Struct. Biol.* **17**, 513–520 (2007).
- Liu, F.T. & Rabinovich, G.A. Galectins as modulators of tumour progression. *Nat. Rev. Cancer* **5**, 29–41 (2005).
- Nieminen, J., Kuno, A., Hirabayashi, J. & Sato, S. Visualization of Galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. *J. Biol. Chem.* **282**, 1374–1383 (2007).
- Zelensky, A.N. & Gready, J.E. The C-type lectin-like domain superfamily. *FEBS J.* **272**, 6179–6217 (2005). [AU: Changed from Zelensky per FEBS J online; correct?]
- Figdor, C.G., van Kooyk, Y. & Adema, G.J. C-type lectin receptors on dendritic cells and Langerhans cells. *Nat. Rev. Immunol.* **2**, 77–84 (2002).
- Appelmelk, B.J. *et al.* Cutting edge: carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. *J. Immunol.* **170**, 1635–1639 (2003).
- Blixt, O. *et al.* Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. *Proc. Natl. Acad. Sci. USA* **101**, 17033–17038 (2004).
- Feinberg, H., Castelli, R., Drickamer, K., Seeberger, P.H. & Weis, W.I. Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins. *J. Biol. Chem.* **282**, 4202–4209 (2007).
- van Vliet, S.J., Saeland, E. & van Kooyk, Y. Sweet preferences of MGL: carbohydrate specificity and function. *Trends Immunol.* **29**, 83–90 (2008).
- Brown, G.D. Dectin-1: a signalling non-TLR pattern-recognition receptor. *Nat. Rev. Immunol.* **6**, 33–43 (2006).
- Rogers, N.C. *et al.* Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. *Immunity* **22**, 507–517 (2005).
- Taylor, M.E. & Drickamer, K. Paradigms for glycan-binding receptors in cell adhesion. *Curr. Opin. Cell Biol.* **19**, 572–577 (2007).
- van Kooyk, Y. & Geijtenbeek, T.B. DC-SIGN: escape mechanism for pathogens. *Nat. Rev. Immunol.* **3**, 697–709 (2003).
- Blixt, O. & Collins, B.E., van den Nieuwenhof, I.M., Crocker, P.R. & Paulson, J.C. Sialoside specificity of the Siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. *J. Biol. Chem.* **278**, 31007–31019 (2003).
- Powell, L.D., Sgroi, D., Sjoberg, E.R., Stamenkovic, I. & Varki, A. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. *J. Biol. Chem.* **268**, 7019–7027 (1993).
- Collins, B.E. *et al.* Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. *Proc. Natl. Acad. Sci. USA* **101**, 6104–6109 (2004).
- Barton, G.M. & Medzhitov, R. Toll-like receptor signaling pathways. *Science* **300**, 1524–1525 (2003).
- Bonifaz, L.C. *et al.* In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. *J. Exp. Med.* **199**, 815–824 (2004).
- Geijtenbeek, T.B., van Vliet, S.J., Engering, A., 't Hart, B.A. & van Kooyk, Y. Self- and nonself-recognition by C-type lectins on dendritic cells. *Annu. Rev. Immunol.* **22**, 33–54 (2004).
- Meyer, S. *et al.* DC-SIGN mediates binding of dendritic cells to authentic pseudo-Lewis<sup>x</sup> glycolipids of *Schistosoma mansoni* cercariae, the first parasite-specific ligand of DC-SIGN. *J. Biol. Chem.* **280**, 37349–37359 (2005).
- Gringhuis, S.I. *et al.* C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF- $\kappa$ B. *Immunity* **26**, 605–616 (2007).
- Hodges, A. *et al.* Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. *Nat. Immunol.* **8**, 569–577 (2007).
- Underhill, D.M., Rossmagale, E., Lowell, C.A. & Simmons, R.M. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. *Blood* **106**, 2543–2550 (2005).
- LeibundGut-Landmann, S. *et al.* Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. *Nat. Immunol.* **8**, 630–638 (2007).
- Bergman, M., Del Prete, G., van Kooyk, Y. & Appelmelk, B. *Helicobacter pylori* phase variation, immune modulation and gastric autoimmunity. *Nat. Rev. Microbiol.* **4**, 151–159 (2006).
- van Liemt, E. *et al.* *Schistosoma mansoni* soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. *Mol. Immunol.* **44**, 2605–2615 (2007).
- Stambach, N.S. & Taylor, M.E. Characterization of carbohydrate recognition by langerin, a C-type lectin of Langerhans cells. *Glycobiology* **13**, 401–410 (2003).
- Geijtenbeek, T.B. *et al.* Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. *Cell* **100**, 575–585 (2000).
- Geijtenbeek, T.B. *et al.* DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. *Cell* **100**, 587–597 (2000).
- de Witte, L. *et al.* Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. *Nat. Med.* **13**, 367–371 (2007).
- Takada, A. *et al.* Human macrophage C-type lectin specific for galactose and N-acetylglucosamine promotes filovirus entry. *J. Virol.* **78**, 2943–2947 (2004).
- Crocker, P.R. Siglecs in innate immunity. *Curr. Opin. Pharmacol.* **5**, 431–437 (2005).
- Blasius, A.L. & Colonna, M. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. *Trends Immunol.* **27**, 255–260 (2006).
- Tateno, H. *et al.* Distinct endocytic mechanism of CD22 (Siglec-2) and Siglec-F reflects roles in cell signaling and innate immunity. *Mol. Cell. Biol.* **27**, 5699–5710 (2007).
- Pelletier, I. *et al.* Specific recognition of *Leishmania major* poly- $\beta$ -galactosyl epitopes by galectin-9: possible implication of galectin-9 in interaction between L. major and host cells. *J. Biol. Chem.* **278**, 22223–22230 (2003).
- van den Berg, T.K. *et al.* LacdiNAc-glycans constitute a parasite pattern for galectin-3-mediated immune recognition. *J. Immunol.* **173**, 1902–1907 (2004).
- Nieminen, J., St-Pierre, C. & Sato, S. Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. *J. Leukoc. Biol.* **78**, 1127–1135 (2005).
- Chen, H.Y. *et al.* Role of galectin-3 in mast cell functions: galectin-3-deficient mast cells exhibit impaired mediator release and defective JNK expression. *J. Immunol.* **177**, 4991–4997 (2006).
- Rabinovich, G.A., Sotomayor, C.E., Riera, C.M., Bianco, I. & Correa, S.G. Evidence of a role for Galectin-1 in acute inflammation. *Eur. J. Immunol.* **30**, 1331–1339 (2000).
- La, M. *et al.* A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. *Am. J. Pathol.* **163**, 1505–1515 (2003).
- Stowell, S.R. *et al.* Human galectin-1, -2, and -4 induce surface exposure of phos-



- phatidylserine in activated human neutrophils but not in activated T cells. *Blood* **109**, 219–227 (2007).
49. Dai, S.Y. *et al.* Galectin-9 induces maturation of human monocyte-derived dendritic cells. *J. Immunol.* **175**, 2974–2981 (2005).
  50. Fulcher, J.A. *et al.* Galectin-1-matured human monocyte-derived dendritic cells have enhanced migration through extracellular matrix. *J. Immunol.* **177**, 216–226 (2006).
  51. MacKinnon, A.C. *et al.* Regulation of alternative activation by galectin-3. *J. Immunol.* **180**, 2650–2658 (2008).
  52. Correa, S.G. *et al.* Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. *Glycobiology* **13**, 119–128 (2003).
  53. Partridge, E.A. *et al.* Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. *Science* **306**, 120–124 (2004).
  54. Garcia-Vallejo, J.J. *et al.* DC-SIGN mediates adhesion and rolling of dendritic cells on primary human umbilical vein endothelial cells through Lewis(X) antigen expressed on ICAM-2. *Mol. Immunol.* [AU: Page and volume numbers?](2007).
  55. van Gisbergen, K.P., Geijtenbeek, T.B. & van Kooyk, Y. Close encounters of neutrophils and DCs. *Trends Immunol.* **26**, 626–631 (2005).
  56. van Vliet, S.J., Gringhuis, S.I., Geijtenbeek, T.B. & van Kooyk, Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. *Nat. Immunol.* **7**, 1200–1208 (2006).
  57. Stillman, B.N. *et al.* Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. *J. Immunol.* **176**, 778–789 (2006).
  58. Paclik, D. *et al.* Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. *J. Mol. Med.* (in the press). [AU: Any update available?]
  59. Fukumori, T. *et al.* CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. *Cancer Res.* **63**, 8302–8311 (2003).
  60. Zhu, C. *et al.* The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. *Nat. Immunol.* **6**, 1245–1252 (2005).
  61. Amano, M., Galvan, M., He, J. & Baum, L.G. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate Galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. *J. Biol. Chem.* **278**, 7469–7475 (2003).
  62. Stowell, S.R. *et al.* Galectins-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. *J. Biol. Chem.* (in the press). [AU: Any update available?]
  63. Rossi, B., Espeli, M., Schiff, C. & Gauthier, L. Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation. *J. Immunol.* **177**, 796–803 (2006).
  64. Collins, B.E., Smith, B.A., Bengtson, P. & Paulson, J.C. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. *Nat. Immunol.* **7**, 199–206 (2006).
  65. Han, S., Collins, B.E., Bengtson, P. & Paulson, J.C. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. *Nat. Chem. Biol.* **1**, 93–97 (2005).
  66. Grewal, P.K. *et al.* ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. *Mol. Cell. Biol.* **26**, 4970–4981 (2006).
  67. Doody, G.M. *et al.* A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. *Science* **269**, 242–244 (1995).
  68. Hoffmann, A. *et al.* Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. *Nat. Immunol.* **8**, 695–704 (2007).
  69. Paulson, J.C., Blixt, O. & Collins, B.E. Sweet spots in functional glycomics. *Nat. Chem. Biol.* **2**, 238–248 (2006).
  70. Buzás, E.I. *et al.* Carbohydrate recognition systems in autoimmunity. *Autoimmunity* **39**, 691–704 (2006).
  71. Toscano, M.A. *et al.* Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. *J. Immunol.* **176**, 6323–6332 (2006).
  72. Perone, M.J. *et al.* Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. *J. Immunol.* **177**, 5278–5289 (2006).
  73. Toscano, M.A. *et al.* Differential glycosylation of T<sub>H</sub>1, T<sub>H</sub>2 and T<sub>H</sub>17 effector cells selectively regulates susceptibility to cell death. *Nat. Immunol.* **8**, 825–834 (2007).
  74. Anderson, A.C. *et al.* Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. *Science* **318**, 1141–1143 (2007).
  75. Hokama, A. *et al.* Induced reactivity of intestinal CD4<sup>+</sup> T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. *Immunity* **20**, 681–693 (2004).
  76. van der Leij, J. *et al.* Strongly enhanced IL-10 production using stable galectin-1 homodimers. *Mol. Immunol.* **44**, 506–513 (2007).
  77. Blois, S.M. *et al.* A pivotal role for galectin-1 in fetomaternal tolerance. *Nat. Med.* **13**, 1450–1457 (2007).
  78. Juszczynski, P. *et al.* The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. *Proc. Natl. Acad. Sci. USA* **104**, 13134–13139 (2007).
  79. Garin, M.I. *et al.* Galectin-1: a key effector of regulation mediated by CD4<sup>+</sup>CD25<sup>+</sup> T cells. *Blood* **109**, 2058–2065 (2007).
  80. Kubach, J. *et al.* Human CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. *Blood* **110**, 1550–1558 (2007).
  81. Demetriou, M., Granovsky, M., Quaggin, S. & Dennis, J.W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. *Nature* **409**, 733–739 (2001).
  82. Chung, C.D., Patel, V.P., Moran, M., Lewis, L.A. & Miceli, M.C. Galectin-1 induces partial TCR  $\zeta$ -chain phosphorylation and antagonizes processive TCR signal transduction. *J. Immunol.* **165**, 3722–3729 (2000).
  83. Kel, J. *et al.* Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis. *Am. J. Pathol.* **170**, 272–280 (2007).
  84. Luca, M.E. *et al.* Mannosylated PLP(139–151) induces peptide-specific tolerance to experimental autoimmune encephalomyelitis. *J. Neuroimmunol.* **160**, 178–187 (2005).
  85. York, M.R. *et al.* A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. *Arthritis Rheum.* **56**, 1010–1020 (2007).
  86. Hakomori, S. Glycosylation defining cancer malignancy: new wine in an old bottle. *Proc. Natl. Acad. Sci. USA* **99**, 10231–10233 (2002).
  87. Dube, D.H. & Bertozzi, C.R. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. *Nat. Rev. Drug Discov.* **4**, 477–488 (2005).
  88. Aarnoudse, C.A., Garcia-Vallejo, J.J., Saeland, E. & van Kooyk, Y. Recognition of tumor glycans by antigen presenting cells. *Curr. Opin. Immunol.* **18**, 105–111 (2006).
  89. Saeland, E. *et al.* The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. *Cancer Immunol. Immunother.* **56**, 1225–1236 (2007).
  90. Kawamura, Y.I. *et al.* Introduction of Sda carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis. *Cancer Res.* **65**, 6220–6227 (2005).
  91. Miyazaki, K. *et al.* Loss of disialyl Lewis<sup>x</sup>, the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-1 (Siglec-7) associated with increased sialyl Lewis<sup>x</sup> expression on human colon cancers. *Cancer Res.* **64**, 4498–4505 (2004).
  92. Tacken, P.J., de Vries, I.J.M., Torensma, R. & Figdor, C.G. Dendritic-cell immunotherapy: from *ex vivo* loading to *in vivo* targeting. *Nat. Rev. Immunol.* **7**, 790–802 (2007).
  93. Idoyaga, J. *et al.* Langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products *in vivo*. *J. Immunol.* **180**, 3647–3650 (2008). [AU: First author changed from Otsuba; correct?]
  94. Rubinstein, N. *et al.* Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. *Cancer Cell* **5**, 241–251 (2004).
  95. Valenzuela, H.F. *et al.* O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by Galectin-1. *Cancer Res.* **67**, 6155–6162 (2007).
  96. Daniels, M.A., Hogquist, K.A. & Jameson, S.C. Sweet 'n' sour: the impact of differential glycosylation on T cell responses. *Nat. Immunol.* **3**, 903–910 (2002).
  97. Comelli, E.M. *et al.* Activation of murine CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes leads to dramatic remodeling of N-linked glycans. *J. Immunol.* **177**, 2431–2440 (2006).
  98. Morgan, R. *et al.* N-Acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. *J. Immunol.* **173**, 7200–7208 (2004).
  99. Bax, M. *et al.* Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by Siglecs and galectins. *J. Immunol.* **179**, 8216–8224 (2007).
  100. Lau, K.S. *et al.* Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. *Cell* **129**, 123–134 (2007).
  101. Grigorian, A. *et al.* Control of T cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. *J. Biol. Chem.* **282**, 20027–20035 (2007).
  102. Togayachi, A. *et al.* Polylactosamine on glycoproteins influences basal levels of lymphocyte and macrophage activation. *Proc. Natl. Acad. Sci. USA* **104**, 15829–15834 (2007).
  103. Green, R.S. *et al.* Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. *Immunity* **27**, 308–320 (2007).
  104. Van Dyken, S.J., Green, R.S. & Marth, J.D. Structural and mechanistic features of protein O glycosylation linked to CD8<sup>+</sup> T-cell apoptosis. *Mol. Cell. Biol.* **27**, 1096–1111 (2007).
  105. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. *Science* **313**, 670–673 (2006).
  106. Arnold, J.N. *et al.* The impact of glycosylation on the biological function and structure of human immunoglobulins. *Annu. Rev. Immunol.* **25**, 21–50 (2007).
  107. Ju, T. & Cummings, R.D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1  $\beta$ 3-galactosyltransferase. *Proc. Natl. Acad. Sci. USA* **99**, 16613–16618 (2002).
  108. An, G. *et al.* Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. *J. Exp. Med.* **204**, 1417–1429 (2007).
  109. Feizi, T. & Chai, W. Oligosaccharide microarrays to decipher the glycode. *Nat. Rev. Mol. Cell Biol.* **5**, 582–588 (2004).